Profile data is unavailable for this security.
About the company
Laboratorios Farmaceuticos ROVI SA (ROVI) is a Spain-based company principally engaged in the pharmaceutical industry. The Company’s main activities include the development and commercialization, nationwide and abroad, of medicines and drugs. Its products are structured into three fields: Diagnostic, which offers contrast mediums for use in magnetic resonance, ultrasound and X-ray diagnostics; Prescription, which distributes medicines under such brands as Hibor, Osseor, Hepadren, Pneumovax-23, Glufan, Corlentor, Exxiv, Calcio y Vitamina D3 Rovi and Absorcol, among others; and Over The Counter (OTC), which comprises the Perspirex, Enerzona, Dentimelo and ColdPack brands. The Company owns such fully consolidated subsidiaries as Gineladius SL, Frosst Iberica SA, Rovi Contract Manufacturing SL and Bertex Pharma GmbH, among others.
- Revenue in EUR (TTM)779.05m
- Net income in EUR137.84m
- Incorporated1946
- Employees2.11k
- LocationLaboratorios Farmaceuticos ROVI SAC/ Julian Camarillo, 35MADRID 28037SpainESP
- Phone+34 913756230
- Fax+34 913047881
- Websitehttps://www.rovi.es/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glenmark Pharmaceuticals Ltd | 1.30bn | -208.58m | 4.37bn | 15.56k | -- | 5.07 | -- | 3.37 | -67.28 | -53.21 | 418.40 | 278.11 | 0.7004 | 1.81 | 4.28 | -- | -10.86 | 1.02 | -15.92 | 1.43 | 62.64 | 61.27 | -15.50 | 1.43 | 0.8447 | 1.19 | 0.1356 | 56.98 | 1.98 | 3.67 | -1,018.93 | -- | -5.89 | 4.56 |
Avidity Biosciences Inc | 9.97m | -209.82m | 4.55bn | 253.00 | -- | 5.37 | -- | 455.83 | -2.95 | -2.95 | 0.1408 | 8.69 | 0.0139 | -- | -- | 42,964.43 | -29.22 | -31.61 | -31.71 | -34.45 | -- | -- | -2,103.78 | -1,540.50 | -- | -- | 0.00 | -- | 3.64 | 90.71 | -21.97 | -- | 143.89 | -- |
Apellis Pharmaceuticals Inc | 480.84m | -382.86m | 4.58bn | 702.00 | -- | 18.71 | -- | 9.53 | -3.46 | -3.46 | 4.33 | 2.20 | 0.5788 | 0.5747 | 3.50 | 746,538.40 | -46.09 | -73.88 | -57.28 | -90.03 | 86.47 | -- | -79.62 | -326.49 | 3.02 | -38.72 | 0.6087 | -- | 425.83 | -- | 18.94 | -- | -- | -- |
Rohto Pharmaceutical Co Ltd | 1.57bn | 179.25m | 4.63bn | 7.26k | 25.01 | 3.13 | 19.93 | 2.95 | 135.21 | 135.21 | 1,183.75 | 1,079.72 | 0.8259 | 2.59 | 4.17 | 37,310,920.00 | 9.57 | 8.54 | 13.02 | 11.79 | 58.07 | 58.59 | 11.59 | 10.30 | 1.93 | -- | 0.0614 | 19.39 | 13.48 | 8.09 | 17.28 | 25.85 | 5.20 | 18.61 |
Richter Gedeon Vegyeszeti Gyar Nyrt | 2.04bn | 479.14m | 4.65bn | 11.60k | 9.59 | 1.51 | 7.60 | 2.28 | 1,020.54 | 1,020.53 | 4,335.98 | 6,494.05 | 0.5724 | 1.46 | 4.05 | 68,856,070.00 | 13.62 | 11.64 | 15.34 | 13.28 | 67.11 | 58.18 | 23.80 | 18.93 | 3.08 | -- | 0.0153 | 39.94 | 0.2993 | 12.57 | -6.05 | 35.06 | 15.59 | 33.94 |
Siegfried Holding AG | 1.31bn | 115.05m | 4.66bn | 3.93k | 38.28 | 5.09 | 23.40 | 3.57 | 26.28 | 26.28 | 298.23 | 197.49 | 0.6958 | 2.27 | 3.14 | 323,288.60 | 6.17 | 6.51 | 7.67 | 7.98 | 25.20 | 23.24 | 8.86 | 9.06 | 1.39 | 7.93 | 0.3468 | 15.26 | 3.41 | 9.87 | -28.16 | 18.34 | 17.95 | 6.72 |
Laboratorios Farmaceuticos ROVI SA | 779.05m | 137.84m | 4.68bn | 2.11k | 33.29 | 8.65 | 29.33 | 6.01 | 2.60 | 2.60 | 14.74 | 10.03 | 0.9364 | 0.9838 | 5.34 | 369,045.00 | 16.56 | 18.90 | 22.75 | 25.58 | 58.01 | 59.82 | 17.69 | 20.13 | 0.771 | 812.80 | 0.135 | 34.37 | 1.44 | 22.30 | -14.69 | 56.93 | 15.84 | 69.11 |
GlaxoSmithKline Pharmaceuticals Limited | 379.35m | 64.80m | 4.86bn | 3.21k | 74.98 | 24.88 | 67.05 | 12.81 | 34.82 | 34.82 | 203.88 | 104.93 | 1.00 | 2.71 | 16.67 | 10,755,860.00 | 17.14 | 11.01 | 29.26 | 17.88 | 61.36 | 55.77 | 17.08 | 12.25 | 1.49 | 466.45 | 0.0104 | 192.07 | 6.21 | 2.00 | -2.91 | 5.78 | -36.02 | 9.86 |
Hikma Pharmaceuticals Plc | 2.64bn | 174.36m | 4.88bn | 8.97k | 28.06 | 2.41 | 13.90 | 1.85 | 0.6595 | 0.6595 | 9.97 | 7.67 | 0.6284 | 1.76 | 3.67 | 247,297.50 | 4.20 | 8.19 | 5.72 | 11.30 | 48.94 | 50.29 | 6.68 | 13.77 | 0.9029 | 7.68 | 0.3503 | 36.71 | 14.22 | 6.73 | 1.06 | -7.59 | 7.97 | 14.03 |
Krka d.d. Novo Mesto | 1.83bn | 323.81m | 4.90bn | 11.80k | 14.26 | 2.04 | 11.50 | 2.67 | 10.48 | 10.48 | 59.36 | 73.17 | 0.6528 | 1.37 | 3.57 | 157,225.70 | 11.51 | 12.64 | 13.68 | 15.12 | 55.99 | 57.29 | 17.64 | 18.71 | 2.88 | 66.70 | 0.0056 | 59.21 | 5.18 | 6.28 | -13.58 | 12.45 | 8.35 | 18.57 |
Organon & Co | 5.82bn | 960.64m | 4.91bn | 10.00k | 5.10 | 110.92 | 4.15 | 0.8432 | 4.08 | 4.08 | 24.71 | 0.1876 | 0.5603 | 2.18 | 4.24 | 634,700.00 | 9.24 | 16.53 | 11.79 | 20.97 | 59.04 | 65.12 | 16.50 | 26.79 | 1.15 | 2.36 | 0.9945 | 8.25 | 1.44 | -8.52 | 11.56 | -13.83 | 20.72 | -- |
BridgeBio Pharma Inc | 200.57m | -493.87m | 5.02bn | 550.00 | -- | -- | -- | 25.04 | -3.23 | -3.23 | 1.29 | -5.61 | 0.2964 | -- | -- | 397,449.10 | -74.13 | -72.44 | -90.19 | -89.72 | 98.91 | 94.41 | -250.09 | -1,225.66 | -- | -11.48 | 2.53 | -- | -88.02 | -- | -33.67 | -- | -40.94 | -- |
Financiere de Tubize SA | 0.00 | 88.15m | 5.04bn | -- | 57.16 | 2.80 | 57.16 | -- | 1.98 | 1.98 | 0.00 | 40.36 | -- | -- | -- | -- | -- | 7.04 | -- | 7.24 | -- | -- | -- | 145.70 | -- | -- | 0.0422 | 20.94 | -- | -- | 3.50 | -20.93 | -- | 11.61 |
Holder | Shares | % Held |
---|---|---|
Capital Research & Management Co. (World Investors)as of 31 Mar 2024 | 1.13m | 2.08% |
T. Rowe Price International Ltd.as of 31 Mar 2024 | 862.55k | 1.60% |
The Vanguard Group, Inc.as of 04 Jul 2024 | 785.11k | 1.45% |
Norges Bank Investment Managementas of 31 Dec 2023 | 549.97k | 1.02% |
Santander Private Banking Gestion SA SGIICas of 31 Dec 2023 | 498.88k | 0.92% |
Dimensional Fund Advisors LPas of 04 Jul 2024 | 377.64k | 0.70% |
RBC Global Asset Management (UK) Ltd.as of 31 May 2024 | 355.96k | 0.66% |
ProfitlichSchmidlin AGas of 30 Apr 2024 | 279.09k | 0.52% |
Invesco Asset Management Ltd.as of 29 Feb 2024 | 276.30k | 0.51% |
Victory Capital Management, Inc. (Investment Management)as of 31 Mar 2024 | 266.45k | 0.49% |